BAXHealthcare · Medical Instruments & SuppliesThe 14 Wall Street analysts covering Baxter International, Inc. hold a median 12-month price target of $28 — +12.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 10 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Baxter International, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (95): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Momentum (46): The shares have been drifting down relative to others.
Size (13): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BAX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +12.9% from it.
Of the 20 most recent actions, 9 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Oct 2026 | Barclays | Initiates | Underweight | $20 |
| 5 Oct 2026 | Citigroup | Maintains | Neutral | $28 → $27 |
| 31 July 2026 | Citigroup | Upgrade | Neutral | — |
| 31 July 2026 | Citigroup | Upgrade | Neutral | $17 → $28 |
| 31 July 2026 | Stifel | Maintains | Hold | — |
| 31 July 2026 | Stifel | Maintains | Hold | $24 → $28 |
| 31 July 2026 | TD Cowen | Maintains | Hold | — |
| 31 July 2026 | TD Cowen | Maintains | Hold | $24 → $29 |
| 31 July 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 31 July 2026 | Wells Fargo | Maintains | Equal-Weight | $19 → $23 |
| 28 July 2026 | Stifel | Maintains | Hold | — |
| 28 July 2026 | Stifel | Maintains | Hold | $19 → $24 |
| 28 July 2026 | UBS | Maintains | Neutral | $19 → $25 |
| 28 July 2026 | UBS | Maintains | Neutral | — |
| 27 July 2026 | TD Cowen | Maintains | Hold | $20 → $24 |
| 27 July 2026 | TD Cowen | Maintains | Hold | — |
| 15 July 2026 | Goldman Sachs | Maintains | Neutral | $19 → $21 |
| 15 July 2026 | Goldman Sachs | Maintains | Neutral | — |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | $22 → $24 |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BAX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 9 Oct 2026, Baxter International, Inc. returned +8.4% against +17.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 8% of US stocks
Cheaper than 66% of US stocks
Cheaper than 44% of US stocks
Cheaper than 35% of US stocks
Higher than 40% of US stocks
Higher than 70% of US stocks
Higher than 42% of US stocks
Higher than 72% of US stocks
Higher than 20% of US stocks
Higher than 34% of US stocks
Higher than 64% of US stocks
Higher than 63% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Baxter International, Inc. has a market value of $12.6B and an enterprise value of $20.1B.
Revenue in the twelve months to 30 June 2026: $11.5B. The latest quarter grew 5.3% year on year.
Net income over the same four quarters: −$1.1B, a −9.3% net margin.
Diluted earnings per share, trailing twelve months: $−2.07.
Free cash flow in the twelve months to 30 June 2026: $812.0M, after $504.0M of capital spending.
Baxter International, Inc. spent $184.0M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 86.3×; forward P/E: 11.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.16%, paying out 155% of earnings.
Baxter International, Inc. employs 37,500 people — $306K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Baxter International, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Baxter said it will host a conference call to discuss third-quarter 2026 financial results on October 29, 2026, at 7:30 a.m. Central Time. The call will be webcast, and participants can pre-register online for call information.
Why it matters — The call is an opportunity for BAX watchers to hear the company’s discussion of its quarterly results.
Zacks Investment Research says its stock-selection approach centers on the Zacks Rank system, which emphasizes earnings estimates and estimate revisions. It also monitors value, growth, and momentum trends.
Why it matters — BAX watchers may note the article frames its discussion around factors Zacks uses to assess stocks, rather than providing a specific Baxter valuation conclusion in the excerpt.
Zacks Investment Research compares Baxter International (BAX) and Bayer Aktiengesellschaft (BAYRY) with their sector performance so far this year. The excerpt does not provide the results of that comparison.
Why it matters — The comparison is relevant to BAX watchers tracking the stock’s performance relative to medical-sector peers, but the excerpt gives no specific performance figures or conclusion.
Baxter announced the release of its inaugural 2026 Connected Hospital Report, based on a survey of 150 information technology and nursing leaders, examining how US hospitals are leveraging technology investments to improve clinical and operational outcomes. The report outlines how hospitals are progressing along a "connected hospital" journey by identifying four distinct stages.
Why it matters — This report signals Baxter's thought leadership and visibility in healthcare technology and connected-hospital solutions, a growth area relevant to BAX's medtech portfolio.
Zacks Investment Research highlights two medical stocks that investors may want to consider, noting that the Zacks Earnings ESP is a useful tool for identifying potential earnings surprises. The article urges investors to take advantage of these opportunities now.
Why it matters — BAX watchers may gain insight into how earnings-surprise signals and sector attention could relate to the broader medical-stock landscape in which Baxter operates.
The 14 Wall Street analysts covering Baxter International, Inc. have a median 12-month price target of $28, with estimates ranging from $20 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Baxter International, Inc., 2 rate it a Buy, 11 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Baxter International, Inc. 89 out of 100 across roughly 4,600 US stocks as at 10 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 10 Oct 2026, Baxter International, Inc. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (95 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +12.9% from the last close, and Ticker Nerd's factor model ranks Baxter International, Inc. 89 out of 100 as at 10 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Baxter International, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BAX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $40 over the next 12 months.
Baxter International, Inc. returned +8.4% over the 12 months to 9 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Baxter International Inc. is a global healthcare company focused on providing essential medical products and technologies used in hospitals, clinics, surgery centers, pharmacies, and home-care settings.
The most recent item we track (Business Wire, 7 Oct 2026): "Baxter to Host Third-Quarter 2026 Financial Results Conference Call for Investors". Baxter said it will host a conference call to discuss third-quarter 2026 financial results on October 29, 2026, at 7:30 a.m. Central Time. The call will be webcast, and participants can pre-register online for call information.
Baxter International Inc. is a global healthcare company focused on providing essential medical products and technologies used in hospitals, clinics, surgery centers, pharmacies, and home-care settings. Baxter International Inc. develops and supplies infusion systems, sterile intravenous solutions, injectable pharmaceuticals, parenteral nutrition therapies, advanced surgery products, patient monitoring and diagnostic technologies, smart beds, and respiratory care devices. The company also supports renal and acute care through therapies and connected solutions that help clinicians deliver treatment across a wide range of care environments. Its portfolio is designed to support everyday healthcare delivery, from critical care and procedural settings to long-term and ambulatory care. Baxter International Inc. plays an important role in the medical technology market by supplying products that are widely used in routine treatment, life-sustaining therapy, and hospital infrastructure.
CEO Mr. Andrew P. Hider · 37,500 employees · United States · https://www.baxter.com
